AnteoTech (ADO) investor relations material

Executive summary

• Cash position of $3.3 million (A$3.291 million) with no debt and an R&D tax rebate claim in progress as of Q1 FY2027, supported by a capital raise in January 2026.

• Two core businesses—Life Sciences and Advanced Battery Technologies—showing commercial and technical momentum in large, growing global markets, with record product samples dispatched and expanding sales pipelines.

• Strategic partnerships and customer base expansion targeted in India, USA, South Korea, Japan, and Europe, with increased presence at international industry forums.

• Initiated new joint product development programs and identified multiple near-term catalysts.

Financial highlights

• Cash balance of $3.3 million (A$3.291 million) and no debt as of 31 March 2026.

• Net cash outflows from operating activities were A$1.6 million for the quarter; customer receipts totaled A$294,000.

• Capital raise in January 2026 issued 245.7 million shares at A$0.0155 per share, raising A$3.5 million net of costs.

• R&D tax rebate claim progressing, expected to further strengthen liquidity.

Outlook and guidance

• Board-approved go-to-market plan for new CLIA product, with pilot market launch in planning and focus on completing the Initial Work Program.

• Key objectives include converting customer sample trials into sales, pipeline growth, and securing strategic partnerships.

• ABT focus on commercial supply arrangements for Ultranode 70, progressing JDA negotiations for Ultranode 95, and expanding US market entry.

• Continued focus on securing new customers in India and expanding global partnerships.